Read by QxMD icon Read

Journal of Clinical Pharmacy and Therapeutics

Zhao-Qi Tang, Rui-Hua Jiang, Hong-Bin Xu
WHAT IS KNOWN AND OBJECTIVE: In this study, the effectiveness of pharmaceutical care on treatment outcomes for patients with first-time pulmonary tuberculosis in China was assessed. METHODS: In this study, patients were randomized either to the usual care (UC) group (n = 72) where patients received routine medical and nursing care or to the pharmaceutical care (PC) group (n = 59) where patients were simultaneously provided with pharmaceutical care. The primary objectives were to evaluate whether treatment outcomes and patient adherence improved more in the PC group than in the UC group...
July 12, 2018: Journal of Clinical Pharmacy and Therapeutics
Paul O Lewis, Emily L Heil, Kelly L Covert, David B Cluck
WHAT IS KNOWN AND OBJECTIVE: Treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a long-standing challenge to health care, often complicated by metastatic infections, treatment failure and mortality. When MRSA bacteraemia persists despite adequate initial treatment, current Infectious Diseases Society of America guidelines recommend evaluation and removal of possible sources of infection. In addition, a change in therapy may be considered. The objective of this review was to explore the therapeutic options for the treatment of persistent MRSA bacteraemia...
July 12, 2018: Journal of Clinical Pharmacy and Therapeutics
T Shibata, Y Nomura, A Takada, S Aoki, M Katashima, H Murakami
WHAT IS KNOWN AND OBJECTIVE: Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor currently being investigated for the treatment of anemia in chronic kidney disease. Lanthanum carbonate is a phosphate binder that is commonly used to treat hyperphosphatemia in patients with chronic kidney disease. This study investigated the effect of lanthanum carbonate on the pharmacokinetics, safety and tolerability of a single oral dose of roxadustat in healthy non-elderly adult male subjects...
July 7, 2018: Journal of Clinical Pharmacy and Therapeutics
A-L Blanc, B Guignard, A Desnoyer, O Grosgurin, C Marti, C Samer, P Bonnabry
WHAT IS KNOWN: Potentially inappropriate medication (PIM) is a risk factor for drug-related problems (DRPs) and an important inpatient safety issue. PIM-Check is a screening tool designed to detect PIM in internal medicine patients. OBJECTIVE: This study aimed to determine whether PIM-Check could help to identify and reduce DRPs. METHOD: Prospective interventional study conducted on patients admitted to internal medicine wards in a university hospital between 1 September 2015 and 30 October 2015...
July 5, 2018: Journal of Clinical Pharmacy and Therapeutics
Satoko Oka, Kazuo Ono, Masaharu Nohgawa
WHAT IS KNOWN AND OBJECTIVES: Optimal strategies for treating patients with very advanced relapsed and refractory multiple myeloma (RRMM) have not been clarified. CASE SUMMARY: A 80-year-old patient with RRMM experienced extramedullary relapse following treatment with bortezomib, lenalidomide and pomalidomide. However, he achieved very good partial remission after retreatment with lenalidomide. WHAT IS NEW AND CONCLUSION: This report illustrates that patients with very advanced RRMM can still respond to prior therapy even after being exposed and refractory to several agents...
July 4, 2018: Journal of Clinical Pharmacy and Therapeutics
Brian L Erstad
WHAT IS KNOWN AND OBJECTIVE: The purpose of this critical narrative review is to analyse studies evaluating the disposition of albumin in critically ill patients and to compare the findings to studies involving healthy subjects and less severely ill patients. COMMENT: PubMed and EMBASE were reviewed for prospective studies involving the disposition of radiolabelled albumin. Studies of normal volunteers, patients undergoing surgical procedures and critically ill patients indicate a relationship between increasing disease acuity or severity and increasing transcapillary escape of albumin...
July 3, 2018: Journal of Clinical Pharmacy and Therapeutics
Pradeep Reddy Kathi, Maher Tama, Shanker Kundumadam, Paul Naylor, Milton Mutchnick
WHAT IS KNOWN AND STUDY OBJECTIVE: Carfilzomib is a newer drug approved for the treatment of relapsing and refractory multiple myeloma. It has been rarely associated with acute liver failure (ALF). CASE SUMMARY: We present a case of 58-year-old man presenting with abnormal liver function tests and subsequently diagnosed with ALF due to carfilzomib. Liver enzymes improved significantly after discontinuation of the drug. WHAT IS NEW AND CONCLUSION: Even though ALF due to carfilzomib has been documented rarely in clinical studies, no detailed case report has been published so far...
July 3, 2018: Journal of Clinical Pharmacy and Therapeutics
Y Guan, F He, J Wu, L Zhao, X Wang, L Huang, G Zeng, B Ren, J Chen, X Liao, Z Ma, X Chen, G Zhong, M Huang, X Zhao
WHAT IS KNOWN AND OBJECTIVE: Jintrolong® is a pegylated recombinant human growth hormone (rhGH) (PEG-rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single-dose Jintrolong® injection in healthy adult subjects. METHODS: Both trials were single-centre, randomized, open-label and single-dose studies. In the human tolerability trial, 34 healthy subjects were randomized to receive single-dose Jintrolong® sc injection (0...
June 29, 2018: Journal of Clinical Pharmacy and Therapeutics
B C Millar, J C Rendall, D G Downey, J E Moore
WHAT IS KNOWN AND OBJECTIVE: Ivacaftor is a novel potentiator of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein, which corrects the gating defect and increases ion-function of activated cell-surface CFTR. Bacteria also regulate their physiology through ion channels. However, little is known about the potential effects of ivacaftor on bacterial ion channels, which, in turn, may have a potential effect on transport across the bacterial cell membrane. Therefore, any change in the ability to transport molecules across cell membranes in bacteria could have an important impact on bacterial transport physiology...
June 29, 2018: Journal of Clinical Pharmacy and Therapeutics
B Crosby, C M Deas
WHAT IS KNOWN AND OBJECTIVE: Combined antiretroviral therapy (ART) reduces human immunodeficiency virus type 1 (HIV-1) RNA plasma levels below the limit of detection. However, HIV-1 persists in latently infected CD4+ T cells, which is currently the barrier to curing HIV-1. Novel mechanisms are being explored to target HIV-1 latent reservoirs. The purpose of this review was to critically evaluate the available literature on innovative use of valproic acid (VPA) for the agent's therapeutic effects on reversing latent human immunodeficiency virus (HIV) reservoirs...
June 29, 2018: Journal of Clinical Pharmacy and Therapeutics
P S Chaw, J Höpner, R Mikolajczyk
WHAT IS KNOWN AND OBJECTIVE: Inappropriate antibiotic use is the leading cause of antibiotic resistance especially in developing countries, where patient management is mainly based on the prescription of medicines due to deficiencies in diagnostic procedures. The objective of this study was to conduct a systematic review of studies on knowledge, attitude and practice of health practitioners towards antibiotic prescribing and resistance in developing countries. METHODS: We used MEDLINE and EMBASE to conduct a systematic search for studies...
June 29, 2018: Journal of Clinical Pharmacy and Therapeutics
D E Zimmerman, L Jachim, A Iaria, C Brun, J R Covvey
WHAT IS KNOWN AND OBJECTIVES: To assess the effect of body weight on the total dose of intravenous (IV) diltiazem needed to reach goal heart rate (HR) for atrial fibrillation (Afib) with rapid ventricular response (RVR) in the emergency department (ED) setting. METHODS: A single-center retrospective cohort was ascertained using electronic medical record data from January 2013 to December 2016. Inclusion criteria consisted of new onset Afib with RVR, receipt of IV diltiazem in the ED, and age ≥18 years old...
June 28, 2018: Journal of Clinical Pharmacy and Therapeutics
M V Ha, M S Choy, D McCoy, N Fernandez, J S Suh
WHAT IS KNOWN AND OBJECTIVE: Candida catenulata is a fungus commonly found in Australian cheeses. C. catenulata has been identified as the causative pathogen for one report of onychomycosis and one report of candidaemia. CASE DESCRIPTION: A 37-year-old male underwent surgery for an incarcerated umbilical hernia repair and bowel obstruction and presented with severe abdominal pain and ascitic fluid draining from the surgical site. C. catenulata was isolated in blood cultures...
June 28, 2018: Journal of Clinical Pharmacy and Therapeutics
J L Revuelta-Herrero, A Giménez-Manzorro, A Matilla-Peña, A Herranz-Alonso, M Sanjurjo-Sáez
WHAT IS KNOWN AND OBJECTIVE: No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). CASE SUMMARY: Three hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12 weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain...
June 28, 2018: Journal of Clinical Pharmacy and Therapeutics
O S Olawoye, B A Adeagbo, O O Bolaji
WHAT IS KNOWN AND OBJECTIVE: Moringa oleifera (MO) Lam (Moringaceae) is commonly used as food supplement and as medicine in most African countries where malaria is also endemic. Therefore, co-administration of MO with antimalarials is a possibility. This study investigated the effects of MO leaves powder on the pharmacokinetics of amodiaquine (AQ) in human subjects. METHODS: Twenty healthy volunteers were recruited for the 3-period study. In the first period, a single dose of AQ tablet (10 mg/kg) was administered orally after an overnight fast...
June 19, 2018: Journal of Clinical Pharmacy and Therapeutics
T Hirai, R Yamaga, A Fujita, T Itoh
WHAT IS KNOWN AND OBJECTIVE: Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) represent the cornerstones of hypertension and congestive heart failure treatment. Risk factors for hyperkalaemia associated with ACEI and ARB are chronic kidney disease and concomitant medications which increase serum potassium level. Body mass index (BMI) also affects pharmacokinetics of ACEI and ARB and potassium disposition. We evaluated the relationship between BMI and hyperkalaemia associated with ACEI and ARB treatments...
June 16, 2018: Journal of Clinical Pharmacy and Therapeutics
J E Yap, P Jaiswal, L Ton, R Szynkarek, B M Attar, S Gandhi
WHAT IS KNOWN AND OBJECTIVE: Elbasvir/grazoprevir is an all-oral regimen approved for patients with hepatitis C virus (HCV) genotypes 1 and 4, and in renal insufficiency. However, to date, no data exist on the efficacy of this regimen when it is crushed and administered through a percutaneous endoscopic gastrostomy (PEG) tube. Here, we illustrate the case of a 63-year-old man who is the only known patient with HCV infection in the English literature to have successfully achieved a sustained viral response (SVR) when elbasvir/grazoprevir oral combination was administered through a PEG tube...
June 15, 2018: Journal of Clinical Pharmacy and Therapeutics
J E Megías-Vericat, E Monte-Boquet, M Martín-Cerezuela, M J Cuéllar-Monreal, M V Tarazona-Casany, P Pérez-Huertas, S Bonanad, J L Poveda-Andrés
WHAT IS KNOWN AND OBJECTIVES: Most of the clotting factor (CF) dispensations to haemophiliac patients are centralized in a few haemophilia treatment centres, necessitating frequent visits and long travel distances. The aim was to evaluate the home delivery programme developed by the Outpatient Pharmaceutical Care Unit (OPCU) through the association of patients (ASHECOVA). METHODS: A specific software programme was designed to communicate the individual CF requirements...
June 15, 2018: Journal of Clinical Pharmacy and Therapeutics
J C Cho
WHAT IS KNOWN AND OBJECTIVE: Due to advances in healthcare and treatment options, there is a need for pharmacists with additional post-graduate residency training. With the growing need for residency-trained pharmacists, obtaining a post-graduate pharmacy residency has become more competitive. The objective of this study was to capture the perspectives of post-graduate year 1 residency programme directors (RPDs) in the United States (US) regarding aspects of a candidate's application and interview they found most important when selecting future residents...
June 14, 2018: Journal of Clinical Pharmacy and Therapeutics
S Kosari, E J Walker, C Anderson, G M Peterson, M Naunton, E Castillo Martinez, S Garg, J Thomas
WHAT IS KNOWN AND OBJECTIVE: Vaccines and other pharmaceuticals are essential medical supplies that require continuous storage at specific temperatures to maintain viability. Power outages can lead to a break in the cold chain, resulting in the degradation of essential medicines. COMMENT: After a power outage, the stability of vaccines and other medicines can be difficult to ascertain. Many public health guidelines therefore recommend discarding potentially compromised pharmaceuticals unless the cold chain can be guaranteed-a costly endeavour...
June 13, 2018: Journal of Clinical Pharmacy and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"